The Capital Grille
1338-46 Chestnut Street
Philadelphia, PA 19107
Date: Wednesday, May 25, 11:30 am. Luncheon presentation at noon.
Program Presenter: Michael Richman, President & CEO
Michael Richman | President & CEO
Mr. Richman brings to NextCure more than 30 years of industry experience including operating in research, project management, intellectual property, business development, and strategic planning. Along with comprehensive experience in corporate development, he has been involved with legal affairs, licensing and project management. Prior to founding NextCure in 2015, Mr. Richman was most recently President and Chief Executive Officer of Amplimmune which was acquired by MedImmune/AstraZeneca in 2013 and had held that position since the company’s founding in 2007. Mr. Richman also served as: (i) an Executive Vice President and Chief Operating Officer of MacroGenics from 2002 to 2007, (ii) the Senior Vice President of Corporate Development and Administration at MedImmune from 2000 to 2002 and (iii) as Vice President of Business Development from 1996 to 2000. From 1985 to 1996, he served in various positions at Chiron (now Novartis) in business development and intellectual property. Mr. Richman also sits on several public and private company Boards. Mr. Richman holds a M.S.B.A. degree in International Business from San Francisco State University and a B.S. degree in Genetics and Molecular Biology from the University of California at Davis.
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or FIND-IO, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies.